VECT - Quest upgraded while Teva downgraded at UBS and VectiveBio scores two new buy initiations in today's analyst action

Growth beyond COVID for Quest DiagnosticsQuest Diagnostics (DGX) is poised for top-line growth even as COVID-19 testing wanes, according to UBS, which has upgraded shares from neutral to buy.Analyst Kevin Caliendo has also upped his price target to $158 from $135, implying upside of 19% from yesterday's close.He expects that post-COVID, the company's top-line growth will accelerate in the mid-single digits."We  believe  underlying  industry  fundamentals  are as healthy as they have been in 15 years with a stable outpatient reimbursement backdrop," Caliendo writes.Lack of profit levers weigh on expansion for TevaUBS has downgraded shares of Teva Pharmaceutical Industries (TEVA) from buy to neutral as questions linger about profit and outstanding litigation.Caliendo has cut his price target to $11 from $15, implying ~2% return from yesterday's close.He notes that key products, such as Ajovy (fremanezumab-vfrm) and Austedo (deutetrabenazine), have started the year slowly, adding that the latter is requiring additional direct-to-consumer costs

For further details see:

Quest upgraded while Teva downgraded at UBS, and VectiveBio scores two new buy initiations in today's analyst action